Verona Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Verona Pharma has a total shareholder equity of $130.5M and total debt of $120.0M, which brings its debt-to-equity ratio to 92%. Its total assets and total liabilities are $381.8M and $251.3M respectively.
Key information
92.0%
Debt to equity ratio
US$120.01m
Debt
| Interest coverage ratio | n/a |
| Cash | US$336.04m |
| Equity | US$130.49m |
| Total liabilities | US$251.33m |
| Total assets | US$381.82m |
Recent financial health updates
Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?
Aug 10
Is Verona Pharma (NASDAQ:VRNA) Using Too Much Debt?
Apr 26Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?
Jan 26Health Check: How Prudently Does Verona Pharma (NASDAQ:VRNA) Use Debt?
Oct 12Does Verona Pharma (NASDAQ:VRNA) Have A Healthy Balance Sheet?
Jun 27Verona Pharma (NASDAQ:VRNA) Has Debt But No Earnings; Should You Worry?
Mar 10Recent updates
Verona Pharma: A Post FDA Approval Analysis
Sep 10Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?
Aug 10Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
Jun 20Verona Pharma: Key Inflection Point Directly Ahead
May 23Is Verona Pharma (NASDAQ:VRNA) Using Too Much Debt?
Apr 26Verona Pharma: A Few Points From The Bull And Bear Case
Feb 15Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?
Jan 26Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data
Jan 19Health Check: How Prudently Does Verona Pharma (NASDAQ:VRNA) Use Debt?
Oct 12Does Verona Pharma (NASDAQ:VRNA) Have A Healthy Balance Sheet?
Jun 27Verona Pharma (NASDAQ:VRNA) Has Debt But No Earnings; Should You Worry?
Mar 10Is Verona Pharma (NASDAQ:VRNA) Using Debt In A Risky Way?
Dec 02Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point
Sep 13Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials
Aug 19Verona Pharma GAAP EPS of -$0.04 beats by $0.23
Aug 09Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
Feb 04Verona Pharma's ensifentrine successful in mid-stage lung disease study; shares up 8%
Feb 02Enrollment completed in Verona Pharma's study of pMDI ensifentrine in COVID-19
Jan 14Verona Pharma EPS beats by $0.15
Oct 29Financial Position Analysis
Short Term Liabilities: VRNA's short term assets ($364.3M) exceed its short term liabilities ($28.0M).
Long Term Liabilities: VRNA's short term assets ($364.3M) exceed its long term liabilities ($223.4M).
Debt to Equity History and Analysis
Debt Level: VRNA has more cash than its total debt.
Reducing Debt: VRNA's debt to equity ratio has increased from 0% to 92% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VRNA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: VRNA has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 13.6% each year.